hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06337227 id: 2/22 briefTitle: Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis overallStatus: RECRUITING date: 2023-10-19 date: 2024-10 date: 2026-10 date: 2024-03-29 date: 2024-04-02 name: IRCCS SYNLAB SDN class: OTHER name: Federico II University briefSummary: The project aims to shed light on the role of Sirtuins, enzymes belonging to the third class of histone deacetylases (class III) involved in epigenetic modifications (deacetylation), focusing mainly on Sirtuin 6 (SIRT6), as a regulator of atherosclerosis and severe aortic valve stenosis through molecular-based and epigenetic studies in human VSMC cells. conditions: Atherosclerosis and Calcific Aortic Stenosis With and Without Diabetes studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 3 type: ESTIMATED name: lncRNA signature analyses measure: To evaluate by analysis of data obtained from NGS techniques whether and which proteins belonging to the Sirtuin family may be deregulated in patients with atherosclerosis or calcific aortic stenosis measure: To evaluate the experimental results achieved in the clinical-diagnostic context sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Irccs Synlab Sdn status: RECRUITING city: Naples zip: 80143 country: Italy name: Monica Franzese, PhD role: CONTACT phone: +393334041413 email: direzionescientifica.irccssdn@synlab.it lat: 40.85216 lon: 14.26811 hasResults: False
nctId: NCT06337214 id: TCHIRB-11301014-E briefTitle: TCM Therapy Program Impact on Breast Cancer Patients' Vital Energy overallStatus: RECRUITING date: 2024-03-13 date: 2025-02-28 date: 2025-02-28 date: 2024-03-29 date: 2024-04-02 name: Taipei City Hospital class: OTHER_GOV briefSummary: The goal of this study is to evaluate the impact of the "Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy" on patients with breast cancer who are currently undergoing conventional Western medical treatments in Taiwan. The main questions it aims to answer are:
This study seeks to integrate the concept of holistic healthcare, emphasizing coordinated care that encompasses physical, mental, and social aspects, into the treatment of breast cancer. conditions: Breast Cancer conditions: Neoplasm, Breast conditions: Patient Participation conditions: Mental Health Issue studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SEQUENTIAL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 80 type: ESTIMATED name: Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy measure: Questionnaire: Constitution in Chinese Medicine Questionnaire measure: Questionnaire: Functional Assessment of Cancer Therapy-General Scale, FACT-G)(Version 4) measure: Questionnaire: European Organisation for Research and Treatment of Cancer, EORTC QLQ-BR23) measure: Additional questions regarding the "Traditional Chinese Medicine Program for Reinforcing Vital Energy" sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei City Hospital status: RECRUITING city: Taipei zip: 10845 country: Taiwan name: Yu-Hsuan Tai, MD role: CONTACT phone: +886918130891 email: daidayangisele@gmail.com,dbb02@tpech.gov.tw lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06337201 id: BTH-6.1.1-0138-2023 briefTitle: A Digital Life Story to Support Person-centred Care for Older Adults With Dementia Perspectives overallStatus: RECRUITING date: 2022-08-15 date: 2026-01 date: 2027-06 date: 2024-03-29 date: 2024-03-29 name: Blekinge Institute of Technology class: OTHER briefSummary: Person-centred care can be supported when healthcare professionals access and actively use the information recorded in a life story. Active use of the life story can create security for a person with dementia and their carers. The written life story describes the person and their life experiences, which can define the person's identity. National guidelines for care and nursing in dementia and Blekinge's regional guidelines emphasise the importance of care and nursing for people with dementia, which should be given with a person-centred approach, where the life story becomes a tool for healthcare professionals. Research shows that a life story can be designed in several ways. For example, in book form, as a brochure, collage, memory box or electronically. The life story is also intended as a tool for healthcare professionals to create security and facilitate communication with the individual. As more and more older adults are using computers and tablets as assistive devices, and it is also becoming more common for healthcare professionals to use, for example, tablets as assistive devices in nursing care, the life story could be shared in digital form as an application and become a living document.
Overall aim: To test an application for the life story with the intention of supporting person-centred care for older adults with dementia and to test whether the application can replace the written completion document. Study I: Exploring the research area of the life story in digital form. Study II: Focus group interviews with healthcare professionals. Study III: Test the application, Min Memoria. Study IV: Observations on the use of the application. conditions: Cognitive Impairment conditions: Dementia studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 30 type: ESTIMATED name: Test of the application Min Memoria measure: Healthcare professionals' experiences using a written life story in the daily care of older adults with dementia measure: Data on the use of a digital life story tool. measure: Observation when using a digital life story sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Blekinge Institute of Technology status: RECRUITING city: Karlskrona state: Blekinge zip: 37179 country: Sweden name: Johan Sanmartin Berglund, MD, PhD role: CONTACT phone: +46455385471 email: johan.sanmartin.berglund@bth.se name: Peter Anderberg, PhD role: CONTACT phone: +46455385436 email: peter.anderberg@bth.se lat: 56.16156 lon: 15.58661 hasResults: False
nctId: NCT06337188 id: AAC PhII briefTitle: Adaptive and Individualized AAC Phase II overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-03-01 date: 2025-03-01 date: 2024-03-29 date: 2024-03-29 name: Altec Inc. class: INDUSTRY name: University of Nebraska briefSummary: The overall objective of this study is to develop an Augmentative and Alternative Communication (AAC) system that is effective in delivering a person-centric communication device that will provide a versatile access method that can automatically learn and adapt to the user's physical abilities by creating a personalized, comprehensive keyboard interface for communication, not otherwise available to people in need of alternative communication. conditions: Communication Disorders studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 20 type: ESTIMATED name: Experimental AAC name: Generic AAC measure: Tele-healthcare Satisfaction Questionnaire - Wearable Technology (TSQ-WT) measure: Information Transfer Rate measure: National Aeronautics and Space Administration (NASA) Task Load Index measure: Character-to-character Movement Time measure: Path Efficiency measure: Frequency of Selecting Word Completion Options measure: Number of Written Disfluencies sex: ALL minimumAge: 6 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06337175 id: 000000230988 briefTitle: Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction overallStatus: RECRUITING date: 2021-06-01 date: 2023-10-30 date: 2024-04-30 date: 2024-03-29 date: 2024-03-29 name: Kafrelsheikh University class: OTHER briefSummary: The investigators evaluated whether the characteristics of ischemic stroke patients, door-to-needle time, and stroke risk factors were predictive variables for different subtypes of post-alteplase hemorrhagic transformation of brain infarction. conditions: Ischemic Stroke conditions: Alteplase Adverse Reaction studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study consisted of two distinct groups. The first group comprised 464 patients who did not experience hemorrhagic infarction, while the second group comprised 152 patients who experienced hemorrhagic infarction. primaryPurpose: TREATMENT masking: NONE count: 600 type: ESTIMATED name: Alteplase name: Alteplase measure: predictors of the hemorrhagic infarction type 1 measure: predictors of the hemorrhagic infarction type 2 measure: predictors of the parenchymal hematoma type 1 measure: predictors of the parenchymal hematoma type 2 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kafr Elsheikh University Hospital status: RECRUITING city: Kafr Ash Shaykh zip: 33155 country: Egypt name: mohamed G. Zeinhom, MD role: CONTACT phone: 2001009606828 email: mohamed_gomaa@med.kfs.edu.eg name: sherihan R ahmed, MD role: CONTACT phone: 2001007481842 email: sherihanrezk2016@gmail.com lat: 31.11174 lon: 30.93991 hasResults: False
nctId: NCT06337162 id: UPCC 20223 id: IRB#855195 type: OTHER domain: University of Pennsylvania IRB briefTitle: Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) acronym: HCC overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2028-09-01 date: 2024-03-29 date: 2024-03-29 name: Abramson Cancer Center at Penn Medicine class: OTHER name: Incyte Corporation briefSummary: This is a pilot safety study of the oral PD-L1 inhibitor INCB099280 in patients with HCC awaiting liver transplant. conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: INCB099280 measure: Acute Cellular Rejection of Liver Transplant Attributed to Study Therapy measure: Acute Cellular Rejection of Liver Transplant Within 3 Months measure: Acute Cellular Rejection of Liver Transplant Within 1 Year measure: Toxicity Rates by Category and Grade measure: Proportion of Patients Downstaged measure: Pathologic Complete Response Rate measure: Recurrence-Free Survival at 1 Year After Transplant measure: Overall Survival at 1 Year After Transplant sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Abramson Cancer Center at University of Pennsylvania city: Philadelphia state: Pennsylvania zip: 19104 country: United States name: Jennifer Walsh role: CONTACT phone: 215-615-5858 email: Jennifer.Walsh4@pennmedicine.upenn.edu lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06337149 id: APHP230348 id: IDRCB: 2023-A00006-39 type: REGISTRY domain: IDRCB ANSM briefTitle: Relationship Between Breathing and Attention in Children With Ondine Syndrome acronym: OndineCo overallStatus: RECRUITING date: 2024-02-29 date: 2025-03-01 date: 2026-09-01 date: 2024-03-29 date: 2024-03-29 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Congenital central hypoventilation syndrome (CCHS) is a rare disorder of autonomic and respiratory regulation that alters oxygen delivery to the brain. CCHS patients are at risk for broad neurocognitive deficits. Patients retain ventilatory activity when awake through a respiratory-related cortical network but the need to mobilise cortical resources to breathe lead to breathing-cognition interferences during cognitive tasks. The purpose of this study is to assess the relationship between breathing pattern and attention in CCHS children conditions: Ondine Syndrome conditions: Congenital Central Hypoventilation Syndrome (CCHS) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task) measure: Wechsler scale measure: Nepsy II test sex: ALL minimumAge: 6 Years maximumAge: 16 Years stdAges: CHILD facility: Robert Debre Hospital status: RECRUITING city: Paris zip: 75019 country: France name: Christophe DELCLAUX, MD, PhD role: CONTACT phone: +331 40 03 41 90 email: christophe.delclaux@aphp.fr name: Benjamin DUDOIGNON, MD role: CONTACT phone: +331 40 03 41 90 email: benjamin.dudoignon@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06337136 id: 2022-A01837-36 briefTitle: neonAtal motoR paTtErn autoMatIc analySis acronym: AIMOTHERNeo overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-05 date: 2026-05 date: 2024-03-29 date: 2024-03-29 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: This project consists in developing a computerized clinical assessment system for newborns that takes into account the four major criteria of the various clinical scales: facial mimicry, cry, posture and movement. Classification of motor patterns according to gestational age at birth The aim of this work is the automated identification of pathological motor patterns related to anoxo-ischemic encephalopathy/brachial plexus paralysis/early neonatal bacterial infection/stroke/etc ... conditions: Automated Computer Analysis conditions: Neonatal Motor Pattern studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: comparison of the computer score with the clinical examination measure: Comparison of the evolution of neurological examination and posture based on the day of life for each patient and each group of patients sex: ALL minimumAge: 1 Day maximumAge: 15 Days stdAges: CHILD facility: Department of paediatric neurological care and intentive care unity (PICU), Raymond Poincaré hospital - APHP city: Garches zip: 92380 country: France lat: 48.84226 lon: 2.18232 hasResults: False
nctId: NCT06337123 id: K-38 briefTitle: Physica TT Tibial Plate Follow up Study overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-12 date: 2027-12 date: 2024-03-29 date: 2024-03-29 name: Limacorporate S.p.a class: INDUSTRY briefSummary: This clinical study aims at evaluating clinical, radiographic, patient-reported outcomes of total knee arthroplasty with Physica TT Tibial Plate in combination with Physica Porous KR or Physica Porous PS up to 2 years after surgery, in order to assess the performance of the devices. Furthermore, ithe objective is to collect short-term survivorship of the implant and the incidence of early complications. conditions: Knee Arthropathy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 130 type: ESTIMATED name: Device: Physica TT TIbial Plate and Physica Porous KR name: Device: Physica TT TIbial Plate and Physica Porous PS measure: Percentage of Knee Society Score (KSS) equal or greater than "Good" (score ≥ 70) 2 years after surgery measure: Changes in Range of Motion over time up to 2 years after surgery measure: Changes in Oxford Knee Score (OKS) over time up to 2 years after surgery. measure: Changes in Forgotten Joint Score (FJS) over time up to 2 years after surgery. measure: Changes in Visual Analogue Scale (VAS) Pain over time up to 2 years after surgery. measure: Radiographic implant evaluation and stability assessment from postoperative (baseline) over time up to 2 years after surgery measure: Survival rate (Kaplan-Meier) at 2 years after surgery measure: Incidence, type and severity of Adverse Device Effects (ADE) and Serious Adverse Device Effects (SADE) up to 2 years follow up sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Casa di Cura San Camillo Hopital city: Forte Dei Marmi state: Lucca zip: 55042 country: Italy name: Alessandro Tripodo role: CONTACT name: Alessandro Tripodo role: PRINCIPAL_INVESTIGATOR lat: 43.96388 lon: 10.17478 facility: Ospedale Privato Accreditato Sol et Salus city: Torre Pedrera state: Rimini zip: 47922 country: Italy name: Marco Fravisini role: CONTACT name: Marco Fravisini role: PRINCIPAL_INVESTIGATOR lat: 44.10694 lon: 12.51274 facility: Casa di Cura Carmona city: Messina zip: 98100 country: Italy name: Marcello La Bruna role: CONTACT name: Marcello La Bruna role: PRINCIPAL_INVESTIGATOR lat: 38.19394 lon: 15.55256 facility: Istituto Clinico Porta Sole city: Perugia zip: 06100 country: Italy lat: 43.1122 lon: 12.38878 hasResults: False
nctId: NCT06337110 id: 20436A briefTitle: A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men overallStatus: NOT_YET_RECRUITING date: 2024-04-05 date: 2024-05-25 date: 2024-05-25 date: 2024-03-29 date: 2024-03-29 name: H. Lundbeck A/S class: INDUSTRY briefSummary: The main goal of this study is to learn about how Lu AF28996 moves into, through, and out of the body after a single dose is given to healthy male participants. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 8 type: ESTIMATED name: Lu AF28996 measure: Total Recovery of the Administered Radiolabelled Drug-related Material (Percentage of Dose in Urine and Faeces) measure: AUC0-infinity: Area Under the Plasma Concentration Curve of Radiolabelled Drug-related Material from Zero to Infinity measure: Cmax: Maximum Observed Plasma Concentration of Radiolabelled Drug-related Material measure: Tmax: Nominal Time Corresponding to the Occurrence of Cmax of Radiolabelled Drug-related Material measure: T½: Apparent Elimination Half-life of Radiolabelled Drug-related Material measure: AUC0-infinity of Lu AF28996 measure: Cmax of Lu AF28996 measure: Tmax of Lu AF28996 measure: T½ of Lu AF28996 sex: MALE minimumAge: 35 Years maximumAge: 60 Years stdAges: ADULT facility: Fortrea Clinical Research Unit Ltd city: Holbeck state: Leeds zip: LS11 9EH country: United Kingdom lat: 53.25 lon: -1.18333 hasResults: False
nctId: NCT06337097 id: 2023-1021 id: NCI-2024-02687 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy overallStatus: RECRUITING date: 2024-02-02 date: 2026-12-31 date: 2028-12-31 date: 2024-03-29 date: 2024-04-29 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects. conditions: Immune Checkpoint Therapy studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 880 type: ESTIMATED name: Troponin surveillance name: Standard of care measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center status: RECRUITING city: Houston state: Texas zip: 77030 country: United States name: Nicolas Palaskas, MD role: CONTACT phone: 713-606-3957 email: nlpalaskas@mdanderson.org name: Nicolas Palaskas, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06337084 id: MNPR-101-D001 briefTitle: Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors overallStatus: RECRUITING date: 2024-04-10 date: 2025-04 date: 2025-06 date: 2024-03-29 date: 2024-04-11 name: Monopar Therapeutics class: INDUSTRY briefSummary: The goal of this study is to test a new PET imaging agent in patients with solid tumors. This tracer is made of a radioactively-labeled monoclonal antibody MNPR-101, and can show where tumors are present in the body using a PET-scan. The investigators will investigate if the new imaging agent correctly shows all tumor lesions. In the future, this method may be useful to help predict who will benefit from certain therapies.
Participants will be injected with the radioactive tracer once. After injection, participants will undergo 3 PET-scans. Each PET-scan will take a maximum of 30 minutes. The PET-scans are on separate days within 10 days after injection of the tracer (e.g., 2 hours after injection plus 3-5 days and 7-10 days after injection). Furthermore, the investigators will take blood samples 6 times (5 mL each). Blood pharmacokinetics (PK) will be measured on Day 1 at 10 min, 1h, 2h, once on Days 3-5, and once on Days 7-10.
The amount of radioactivity injected will range between 37-74 MBq (±10%). conditions: Solid Tumor, Adult conditions: Bladder Cancer conditions: Urothelial Carcinoma conditions: Triple-negative Breast Cancer conditions: Lung Cancer conditions: Colorectal Cancer conditions: Gastric Cancer conditions: Ovarian Cancer conditions: Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 12 type: ESTIMATED name: Diagnostic Test: MNPR-101-DFO*-89Zr PET Scan measure: assess dosimetry and biodistribution of product measure: assess tumor Standard Uptake Values (SUV) of product measure: assess pharmacokinetics (PK) levels of product measure: assess tumor uptake to background and tumor uptake to liver ratios of product sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Melbourne Theranostic Innovation Centre (MTIC) status: RECRUITING city: North Melbourne state: Victoria zip: 3051 country: Australia name: Referral Coordinator role: CONTACT phone: 03 9454 5800 lat: -37.80132 lon: 144.95822 hasResults: False
nctId: NCT06337071 id: AM2023MCV4Ⅱ briefTitle: A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2024-06 date: 2025-06 date: 2024-03-29 date: 2024-03-29 name: Aimei Vacin BioPharm (Zhejiang) Co., Ltd. class: INDUSTRY briefSummary: The purpose of this study was to explore the safety and immunogenicity of the experimental vaccine compared with the control vaccines. It is planed to enroll a total of 1,200 subjects, including 300 subjects in each of the 3-5 months old, 6-11 months old, 12-23 months old and 2-15 years old groups, who will be randomly assigned to the trial in a 1:1 ratio to study group or control group. The 3-5 month-old group will have three doses vaccination at 0, 1 and 2 month, and a booster dose at 12 months of age; the 6-11month-old and 12-23 month-old groups will each have total two doses vaccination; the 2-15 year-old group will have one dose vaccination. conditions: Meningococcal Meningitis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1200 type: ESTIMATED name: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine name: ACYW135 Meningococcal Polysaccharide Vaccine measure: Immunogenicity 1 measure: Immunogenicity 2 measure: Immunogenicity 3 measure: Safety 1 measure: Immunogenicity 4 measure: Immunogenicity 5 measure: Immunogenicity 6 measure: Immunogenicity 7 measure: Immunogenicity 8 measure: Immune persistence 1 measure: Immune persistence 2 measure: Safety 2 measure: Safety 3 measure: Safety 4 sex: ALL minimumAge: 3 Months maximumAge: 15 Years stdAges: CHILD facility: Yunnan Center For Disease Control and Prevention city: Kunming state: Yunnan zip: 650022 country: China name: ZHENG Yan role: CONTACT phone: +8687163627796 email: yaqueer_zy@163.com lat: 25.03889 lon: 102.71833 hasResults: False